IL316616A - ROCK2 inhibitors - Google Patents

ROCK2 inhibitors

Info

Publication number
IL316616A
IL316616A IL316616A IL31661624A IL316616A IL 316616 A IL316616 A IL 316616A IL 316616 A IL316616 A IL 316616A IL 31661624 A IL31661624 A IL 31661624A IL 316616 A IL316616 A IL 316616A
Authority
IL
Israel
Prior art keywords
rock2
inhibitors
Prior art date
Application number
IL316616A
Other languages
English (en)
Hebrew (he)
Original Assignee
Graviton Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graviton Bioscience Bv filed Critical Graviton Bioscience Bv
Publication of IL316616A publication Critical patent/IL316616A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL316616A 2022-04-29 2023-04-29 ROCK2 inhibitors IL316616A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263336667P 2022-04-29 2022-04-29
PCT/IB2023/054494 WO2023209692A1 (en) 2022-04-29 2023-04-29 Inhibitors of rock2

Publications (1)

Publication Number Publication Date
IL316616A true IL316616A (en) 2024-12-01

Family

ID=86604437

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316616A IL316616A (en) 2022-04-29 2023-04-29 ROCK2 inhibitors

Country Status (9)

Country Link
US (1) US20250289807A1 (enExample)
EP (1) EP4514466A1 (enExample)
JP (1) JP2025514382A (enExample)
KR (1) KR20250019030A (enExample)
CN (1) CN119604496A (enExample)
AU (1) AU2023262720A1 (enExample)
CA (1) CA3250707A1 (enExample)
IL (1) IL316616A (enExample)
WO (1) WO2023209692A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026502949A (ja) 2022-12-30 2026-01-27 アヴィセンナ バイオサイエンシズ インコーポレイテッド アザインドールrock阻害剤
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity
WO2026011129A1 (en) * 2024-07-03 2026-01-08 Avicenna Biosciences, Inc. Azaindole rock inhibitors for the treatment of medical disorders
CN120204259B (zh) * 2025-04-17 2025-11-18 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) Rock2抑制剂及其在制备治疗胆管癌的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
JP7399848B2 (ja) * 2017-09-01 2023-12-18 カドモン コーポレイション,リミティド ライアビリティ カンパニー Rho関連コイルドコイル含有プロテインキナーゼの阻害剤

Also Published As

Publication number Publication date
WO2023209692A1 (en) 2023-11-02
CN119604496A (zh) 2025-03-11
JP2025514382A (ja) 2025-05-02
KR20250019030A (ko) 2025-02-07
US20250289807A1 (en) 2025-09-18
CA3250707A1 (en) 2023-11-02
AU2023262720A1 (en) 2024-12-12
EP4514466A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
IL320739A (en) rock2 inhibitors
ZA202212146B (en) Inhibitors of nek7 kinase
IL321357A (en) KIF18A inhibitors and their uses
HUE072981T2 (hu) Azakinolinok mint CD38 gátlók
IL314049A (en) PARP7 inhibitors
HUE068818T2 (hu) Transzglutamináz inhibitorok
IL313548A (en) MET kinase inhibitors
EP4263520A4 (en) HETEROCYCLIC PCSK9 INHIBITORS
HUE068724T2 (hu) Transzglutaminázok inhibitorai
EP4237452A4 (en) ANGIOGENIC FACTOR INHIBITORS
IL309077A (en) Transglutaminase inhibitors
EP4100065A4 (en) USE OF MIRNA-485 INHIBITORS TO TREAT TAUOPATHY
IL326113A (en) Methods of using factor b inhibitors
EP4405346A4 (en) SMALL MOLECULE INHIBITORS OF TEAD-YAP
CA3273444A1 (en) Inhibitors of rock2
HK40122640A (en) Inhibitors of rock2
GB202203181D0 (en) Inhibitors of elF4A
GB202107612D0 (en) Inhibitors of metallo-beta-lactamases
HK40086963A (en) Inhibitors of sarm1
HK40075448A (en) Inhibitors of sarm1
CA3310968A1 (en) Inhibitors of parg
CA3289184A1 (en) Heteroarylindole inhibitors of apol-1
HK40120822A (zh) Parg抑制剂
HK40120706A (en) Inhibitors of parg
CA3280853A1 (en) Inhibitors of synaptogyrin-3 expression